Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.26
NAS:SCMP's Cash-to-Debt is ranked lower than
81% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NAS:SCMP: 0.26 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:SCMP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.26  Med: 3.62 Max: No Debt
Current: 0.26
Equity-to-Asset 0.10
NAS:SCMP's Equity-to-Asset is ranked lower than
97% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:SCMP: 0.10 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:SCMP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.45 Max: 0.86
Current: 0.1
-0.21
0.86
Debt-to-Equity 7.41
NAS:SCMP's Debt-to-Equity is ranked lower than
99% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NAS:SCMP: 7.41 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:SCMP' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.46  Med: 1.36 Max: 11.06
Current: 7.41
-0.46
11.06
Debt-to-EBITDA -2.88
NAS:SCMP's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. NAS:SCMP: -2.88 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:SCMP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -28.04  Med: 3.47 Max: 4.48
Current: -2.88
-28.04
4.48
Piotroski F-Score: 4
Altman Z-Score: 0.51
Beneish M-Score: -4.09
WACC vs ROIC
6.45%
-34.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % -44.03
NAS:SCMP's Operating Margin % is ranked lower than
83% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NAS:SCMP: -44.03 )
Ranked among companies with meaningful Operating Margin % only.
NAS:SCMP' s Operating Margin % Range Over the Past 10 Years
Min: -44.03  Med: 17.01 Max: 29.02
Current: -44.03
-44.03
29.02
Net Margin % -60.24
NAS:SCMP's Net Margin % is ranked lower than
84% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. NAS:SCMP: -60.24 )
Ranked among companies with meaningful Net Margin % only.
NAS:SCMP' s Net Margin % Range Over the Past 10 Years
Min: -60.24  Med: 7.94 Max: 22.25
Current: -60.24
-60.24
22.25
ROE % -136.63
NAS:SCMP's ROE % is ranked lower than
94% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. NAS:SCMP: -136.63 )
Ranked among companies with meaningful ROE % only.
NAS:SCMP' s ROE % Range Over the Past 10 Years
Min: -136.63  Med: 14.17 Max: 39.55
Current: -136.63
-136.63
39.55
ROA % -33.34
NAS:SCMP's ROA % is ranked lower than
86% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. NAS:SCMP: -33.34 )
Ranked among companies with meaningful ROA % only.
NAS:SCMP' s ROA % Range Over the Past 10 Years
Min: -33.34  Med: 4.54 Max: 19.13
Current: -33.34
-33.34
19.13
ROC (Joel Greenblatt) % -193.73
NAS:SCMP's ROC (Joel Greenblatt) % is ranked lower than
85% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. NAS:SCMP: -193.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:SCMP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -193.73  Med: 82.98 Max: 529.23
Current: -193.73
-193.73
529.23
3-Year Revenue Growth Rate 35.70
NAS:SCMP's 3-Year Revenue Growth Rate is ranked higher than
93% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NAS:SCMP: 35.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:SCMP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.2  Med: 22.7 Max: 128.6
Current: 35.7
-21.2
128.6
3-Year EBITDA Growth Rate 78.50
NAS:SCMP's 3-Year EBITDA Growth Rate is ranked higher than
95% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NAS:SCMP: 78.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:SCMP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19.8  Med: 67.8 Max: 206.8
Current: 78.5
-19.8
206.8
3-Year EPS without NRI Growth Rate 37.90
NAS:SCMP's 3-Year EPS without NRI Growth Rate is ranked higher than
84% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NAS:SCMP: 37.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:SCMP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.3  Med: 2.9 Max: 82.5
Current: 37.9
-56.3
82.5
GuruFocus has detected 4 Warning Signs with Sucampo Pharmaceuticals Inc NAS:SCMP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:SCMP's 30-Y Financials

Financials (Next Earnings Date: 2018-03-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

SCMP Guru Trades in Q4 2016

Paul Tudor Jones 67,811 sh (New)
Joel Greenblatt 55,508 sh (New)
Leon Cooperman 50,000 sh (New)
Chuck Royce 782,023 sh (+40.57%)
Jim Simons 1,459,800 sh (+7.89%)
Steven Cohen 133,100 sh (-22.44%)
» More
Q1 2017

SCMP Guru Trades in Q1 2017

Joel Greenblatt 219,916 sh (+296.19%)
Chuck Royce 974,023 sh (+24.55%)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Paul Tudor Jones 67,771 sh (-0.06%)
Jim Simons 1,111,400 sh (-23.87%)
» More
Q2 2017

SCMP Guru Trades in Q2 2017

Chuck Royce 1,067,923 sh (+9.64%)
Jim Simons 810,600 sh (-27.06%)
Joel Greenblatt 85,967 sh (-60.91%)
Paul Tudor Jones 16,586 sh (-75.53%)
» More
Q3 2017

SCMP Guru Trades in Q3 2017

Steven Cohen 1,863,435 sh (New)
Jim Simons 1,305,700 sh (+61.08%)
Chuck Royce 1,171,731 sh (+9.72%)
Paul Tudor Jones Sold Out
Joel Greenblatt 39,830 sh (-53.67%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Reduce -53.67%0.01%$10.05 - $13.1 $ 17.0052%39,830
Joel Greenblatt 2017-06-30 Reduce -60.91%0.02%$9.45 - $11 $ 17.0067%85,967
Joel Greenblatt 2017-03-31 Add 296.19%0.02%$10.25 - $13.95 $ 17.0046%219,916
Leon Cooperman 2017-03-31 Sold Out 0.03%$10.25 - $13.95 $ 17.0046%0
Joel Greenblatt 2016-12-31 New Buy0.01%$10.95 - $17.15 $ 17.0022%55,508
Leon Cooperman 2016-12-31 New Buy0.03%$10.95 - $17.15 $ 17.0022%50,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:HKSE:00932, TSE:3341, SZSE:300519, HKSE:00950, NAS:PETQ, HKSE:02633, XKRX:249420, SZSE:002826, XKRX:086450, XKRX:243070, ROCO:4123, SHSE:603520, SZSE:300534, NAS:KPTI, TSE:3151, MIC:OTCP, SZSE:300452, XBRU:MITRA, NAS:COLL, BSP:OFSA3 » details
Traded in other countries:R3A.Germany,
Headquarter Location:USA
Sucampo Pharmaceuticals Inc is a pharmaceutical company having its primary market in the United States. It generates revenue from the sale of drugs for the treatment of gastrointestinal diseases.

Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.

Top Ranked Articles about Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Investor Conference
Sucampo Pharmaceuticals Announces its Participation at the Global Mizuho Investor Conference
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare Conference
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 29th Annual Piper Jaffray Healthcare Conference
Sucampo to Host 2017 R&D Day on November 16 in New York
Stocks Move Ahead of Fed Decision 4 companies affected by earnings results
In Wednesday trading, markets were in green ahead of the Federal Reserve's decision to keep interest rates unchanged, but with a probable hike in December. Read more...
Sucampo Announces Third Quarter 2017 Earnings Call
Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation
Sucampo Pharmaceuticals Announces Presentation at Deutsche Bank’s 25th Annual Leveraged Finance Conference
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

Ratios

vs
industry
vs
history
Forward PE Ratio 11.16
SCMP's Forward PE Ratio is ranked higher than
81% of the 74 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.53 vs. SCMP: 11.16 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 20.00
SCMP's PB Ratio is ranked lower than
96% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. SCMP: 20.00 )
Ranked among companies with meaningful PB Ratio only.
SCMP' s PB Ratio Range Over the Past 10 Years
Min: 0.97  Med: 4.69 Max: 20.28
Current: 20
0.97
20.28
PS Ratio 3.55
SCMP's PS Ratio is ranked higher than
59% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. SCMP: 3.55 )
Ranked among companies with meaningful PS Ratio only.
SCMP' s PS Ratio Range Over the Past 10 Years
Min: 1.2  Med: 3.02 Max: 9.7
Current: 3.55
1.2
9.7
Price-to-Free-Cash-Flow 44.92
SCMP's Price-to-Free-Cash-Flow is ranked higher than
56% of the 212 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.72 vs. SCMP: 44.92 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SCMP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.67  Med: 27.84 Max: 326.79
Current: 44.92
3.67
326.79
Price-to-Operating-Cash-Flow 44.24
SCMP's Price-to-Operating-Cash-Flow is ranked lower than
55% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.64 vs. SCMP: 44.24 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SCMP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.62  Med: 27.38 Max: 160.85
Current: 44.24
3.62
160.85
EV-to-EBIT -7.66
SCMP's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. SCMP: -7.66 )
Ranked among companies with meaningful EV-to-EBIT only.
SCMP' s EV-to-EBIT Range Over the Past 10 Years
Min: -2724.9  Med: 12 Max: 51.3
Current: -7.66
-2724.9
51.3
EV-to-EBITDA -9.94
SCMP's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. SCMP: -9.94 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -746  Med: 8.1 Max: 193.6
Current: -9.94
-746
193.6
EV-to-Revenue 4.03
SCMP's EV-to-Revenue is ranked higher than
50% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. SCMP: 4.03 )
Ranked among companies with meaningful EV-to-Revenue only.
SCMP' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 3 Max: 9.1
Current: 4.03
0.1
9.1
Current Ratio 5.11
SCMP's Current Ratio is ranked higher than
78% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. SCMP: 5.11 )
Ranked among companies with meaningful Current Ratio only.
SCMP' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.7 Max: 9.5
Current: 5.11
1.27
9.5
Quick Ratio 4.46
SCMP's Quick Ratio is ranked higher than
77% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. SCMP: 4.46 )
Ranked among companies with meaningful Quick Ratio only.
SCMP' s Quick Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.68 Max: 9.21
Current: 4.46
1.27
9.21
Days Inventory 126.45
SCMP's Days Inventory is ranked lower than
54% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. SCMP: 126.45 )
Ranked among companies with meaningful Days Inventory only.
SCMP' s Days Inventory Range Over the Past 10 Years
Min: 2.34  Med: 69.48 Max: 164.56
Current: 126.45
2.34
164.56
Days Sales Outstanding 48.23
SCMP's Days Sales Outstanding is ranked higher than
85% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. SCMP: 48.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.75  Med: 19.46 Max: 68.22
Current: 48.23
1.75
68.22
Days Payable 33.48
SCMP's Days Payable is ranked lower than
56% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. SCMP: 33.48 )
Ranked among companies with meaningful Days Payable only.
SCMP' s Days Payable Range Over the Past 10 Years
Min: 9.38  Med: 92.95 Max: 662.06
Current: 33.48
9.38
662.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.30
SCMP's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. SCMP: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SCMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.6  Med: -0.65 Max: 0
Current: -2.3
-9.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 3.87
SCMP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
58% of the 306 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. SCMP: 3.87 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SCMP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.1  Med: 3.12 Max: 230
Current: 3.87
0.1
230
Price-to-Median-PS-Value 1.18
SCMP's Price-to-Median-PS-Value is ranked higher than
77% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. SCMP: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SCMP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.67  Med: 0.98 Max: 2.46
Current: 1.18
0.67
2.46
Earnings Yield (Greenblatt) % -13.05
SCMP's Earnings Yield (Greenblatt) % is ranked lower than
90% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. SCMP: -13.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SCMP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28  Med: 4.9 Max: 125.2
Current: -13.05
-28
125.2

More Statistics

Revenue (TTM) (Mil) $250.47
EPS (TTM) $ -3.28
Beta0.48
Short Percentage of Float20.95%
52-Week Range $9.30 - 17.55
Shares Outstanding (Mil)46.64

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 253 264 307 374
EPS ($) 1.20 1.50 1.88 2.76
EPS without NRI ($) 1.20 1.50 1.88 2.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}